Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceutical First Biochemical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the oxytocin injection and octreotide acetate injection, allowing these drugs to be marketed [1] Group 1: Product Approvals - The oxytocin injection is primarily used for induction of labor, postpartum hemorrhage, and assessing placental reserve function [1] - The octreotide acetate injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyuan Biochemical Pharmaceutical Co., Ltd., received drug registration certificates from the Philippines Food and Drug Administration for the approval of Oxytocin Injection and Acetate Octreotide Injection for market launch [1] Group 1: Product Approvals - Oxytocin Injection is primarily used for induction of labor, postpartum hemorrhage due to uterine atony, and assessing placental reserve function [1] - Acetate Octreotide Injection is mainly used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing postoperative complications from pancreatic surgery, and managing esophageal variceal bleeding [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical, has received drug registration certificates for oxytocin injection and octreotide acetate injection in the Philippines, allowing them to enter the market without significant R&D costs [1] Group 1: Product Details - Oxytocin is used for induction of labor and was approved in China in 1994 [1] - Octreotide acetate is used for treating acromegaly and was approved in China in 2006, passing the consistency evaluation for generic drugs in 2022 [1] Group 2: Market Impact - The sales forecast for oxytocin in the Philippines is estimated at $970,000 in 2024 [1] - The approval of these drugs is expected to help expand the company's overseas market presence [1] Group 3: Financial Considerations - The registration costs for these drugs were approximately 50,000 yuan, with no additional R&D expenses incurred [1] - Sales may face uncertainties due to factors such as policy changes and exchange rate fluctuations [1]

Core Viewpoint - Shanghai Pharmaceuticals Holding Co., Ltd. is a major pharmaceutical group listed in both Shanghai and Hong Kong, focusing on innovation and health improvement [1] Group 1: Stock Performance - On August 18, the Shanghai Composite Index rose by 0.85%, closing at 3728.03 points, while the Hang Seng Index fell by 0.37%, closing at 25176.85 points [1] - Shanghai Pharmaceuticals' A-shares closed at 18.95 yuan, with an increase of 0.74%, while its H-shares closed at 12.67 Hong Kong dollars, decreasing by 0.39% [1] Group 2: Company Overview - Shanghai Pharmaceuticals is included in the Shanghai Stock Exchange 180 Index, the CSI 300 Index, and the Morgan Stanley China Index (MSCI) [1] - The company promotes core values of "innovation, integrity, cooperation, inclusiveness, and responsibility," aiming to enhance public health and become a respected leading brand in pharmaceutical manufacturing and health services [1] Group 3: Business Strategy - The company is committed to continuous innovation and has been increasing its investment in research and development to accelerate its transformation [1]

董事會會議通告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 董事會會議將於二零二五年八月二十八日（星期四）舉行，藉以（其中包括） 批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績及其 發佈。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年八月十八日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 * 僅供識別 ...

Core Viewpoint - Recently, Shanghai Pharmaceuticals (601607) established a new subsidiary, Up Pharmaceutical Holdings (Yongzhou) Co., Ltd., with a registered capital of 20 million yuan, indicating an expansion in its operational capabilities in the pharmaceutical sector [1] Company Summary - The new company is co-owned by Shanghai Pharmaceuticals' subsidiary, Up Pharmaceutical Holdings (Hunan) Co., Ltd., and Yongzhou Big Health Industry Co., Ltd., reflecting a strategic partnership in the health industry [1] - The business scope of the new entity includes drug wholesale, sales of Class II and III radiation devices, operation of Class III medical devices, general equipment repair, and professional design services, showcasing a diverse range of services [1]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 726,500 yuan [1] Group 1: Salary Distribution - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] - The average annual salary for company secretaries in the pharmaceutical commercial sector is 726,500 yuan [1] - Salary distribution shows that 43% earn below 500,000 yuan, 36% earn between 500,000 and 1 million yuan, 18% earn between 1 million and 2 million yuan, and 3% earn above 2 million yuan [1] Group 2: Age and Education Distribution - Company secretaries aged between 40-50 years constitute 57% of the market, while those over 50 years account for 11%, and those aged 40 or below make up 32% [1] - The educational background of company secretaries shows that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one individual holding a PhD [1] Group 3: Notable Salary Changes - The highest-paid company secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [1] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [1]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1-2 million yuan, and 3% above 2 million yuan [2] - The top three highest-paid secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 当视角进一步聚焦至中国经济中心上海时，该地区的医药生物行业CFO薪酬溢价效应更为明显。统计范 围内的39家上海医药生物企业，CFO薪酬总额达4442.62万元，其平均年薪跃升至约113.91万元（中位数 102.20万元）。 这一数字相比全市场CFO平均薪酬高出39.8%（约32.43万元），凸显了上海作为高运营成本、高人才竞 争核心区域，叠加医药生物这一高附加值行业的强力薪酬溢价。 在上海地区医药生物行业上市公司CFO薪酬榜单中，奥浦迈（股票代码：688293.SH）的首席财务官倪 亮萍女士以140.29万元的年薪位列第九位。其2023年年薪为141.60万元，2024年略有下降，变化额 为-1.31万元，变化率为-0.93%。 倪亮萍女士在财务管理领域拥有丰富经验。公开资料显示，倪亮萍出生于1984年，毕业于上海财经大 学，目前为中欧国际商学院EMBA在读。她持有英国皇家特许管理会计师证书（CIMA）和全球特许管 理会计师证书（CGMA）。 在加入奥浦迈之前，倪亮萍女士的职业履历主要包括：2008年至2018年间历 ...

聚焦行业层面，医药生物行业（申万一级）进入统计的395家上市公司CFO平均年薪约为91.97万元（中位数约74.23万元，合计金额3.63亿元），这表明该行业CFO的薪酬水平已显著高于全市 当我们进一步将目光锁定核心区域上海，其医药生物行业的CFO薪酬水平跃升趋势更为明显。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 新浪财经《2024年度A股CFO数据报告》最新出炉，揭示了上市公司财务总监群体的薪酬格局。数据显示，2024年A股上市公司财务总监（CFO）薪酬总额达42.70亿元，平均年薪为81.48万元 区域溢价显著：上海医药生物CFO薪酬高地 分析上海医药CFO薪酬登顶现象，我们认为，这不仅是资深财务高管价值在优质企业的体现，更是上海作为核心城市吸引和留住顶尖金融管理人才的典型缩影，生动诠释了报告所揭示的区域与行 声明：本文由AI大模型生成。市场有风险，投资需谨慎。数据来源于choice，截止2024年末任期不满1年的不参与统计。 这一现象清晰地表明，尽管年度薪酬出现回调，但上海医药首席财务官这一核心岗位本身的价值评估、职责份量以及其在区域人才市场中的标杆地 ...